1.
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
by Krueger, James G., MD
Journal of allergy and clinical immunology, 2012, Vol.130 (1), p.145-154.e9
2.
The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
by Garcês, Sandra
Annals of the rheumatic diseases, 2013, Vol.72 (12), p.1947-1955
3.
Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody
by Mailly, Laurent
Nature biotechnology, 2015, Vol.33 (5), p.549-554
4.
The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region
by van Schie, K A
Annals of the rheumatic diseases, 2015, Vol.74 (1), p.311-314
5.
Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation
by MacGlashan, Donald W., MD, PhD
Journal of allergy and clinical immunology, 2013, Vol.132 (4), p.906-911.e4
6.
A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies
by Garcês, Sandra
Annals of the rheumatic diseases, 2014, Vol.73 (6), p.1138-1143
7.
No added sugar: antibody makers find an upside to 'no fucose'
by Garber, Ken
Nature biotechnology, 2018, Vol.36 (11), p.1025-1026
8.
An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptors
by Shiung, Yu-Yu
Immunobiology (1979), 2011, Vol.217 (7), p.676-683
9.
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα
by Eriksson, C
Annals of the rheumatic diseases, 2005, Vol.64 (3), p.403-407
10.
The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD
by Ben-Horin, S.
Alimentary pharmacology & therapeutics, 2012, Vol.35 (6), p.714-722
11.
Ipilimumab (Yervoy) and the TGN1412 catastrophe
by Bakacs, Tibor
Immunobiology (1979), 2011, Vol.217 (6), p.583-589
12.
Mechanisms of Monoclonal Antibody-Drug Interactions
by HONGHUI ZHOU
Annual review of pharmacology and toxicology, 2011, Vol.51 (1), p.359-372
13.
Immune checkpoint inhibitors in lung cancer: an update
by Sullivan, Kevin
Future oncology (London, England), 2017, Vol.13 (11), p.955-959
14.
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
by Zost, Seth J
Nature medicine, 2020, Vol.26 (9), p.1422-1427
15.
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
by Chen, Rita E
Nature medicine, 2021, Vol.27 (4), p.717-726
16.
The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients:adaptation of INNOVATE to Sweden
by Dewilde, S
Current medical research and opinion, 2006, Vol.22 (9), p.1765-1776
17.
Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope
by Sandercock, Colin G
Nature biotechnology, 2012, Vol.30 (7), p.615-618
18.
A protective chimeric antibody to tick-borne encephalitis virus
by Baykov, Ivan K
Vaccine, 2014, Vol.32 (29), p.3589-3594
19.
Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD
by Steenholdt, C.
Alimentary pharmacology & therapeutics, 2012, Vol.36 (5), p.499-500
20.
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
by Heery, Christopher R, MD
The lancet oncology, 2017, Vol.18 (5), p.587-598
